May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Treatment of Persistent Corneal Epithelial Defects With Plasma Rich in Growth Factors
Author Affiliations & Notes
  • J. A. Duran
    ICQO, Instituto de Oftalmologia, Vizcaya, Spain
  • A. Acera
    ICQO, Instituto de Oftalmologia, Vizcaya, Spain
  • G. Rocha
    ICQO, Instituto de Oftalmologia, Vizcaya, Spain
  • S. López-Plandolit
    ICQO, Instituto de Oftalmologia, Vizcaya, Spain
  • Footnotes
    Commercial Relationships J.A. Duran, None; A. Acera, None; G. Rocha, None; S. López-Plandolit, None.
  • Footnotes
    Support Fundación Gangoiti
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 784. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. A. Duran, A. Acera, G. Rocha, S. López-Plandolit; Treatment of Persistent Corneal Epithelial Defects With Plasma Rich in Growth Factors. Invest. Ophthalmol. Vis. Sci. 2007;48(13):784.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the efficacy of topical application of PRGF (Plasma Rich in Growth Factors) to eyes with persistent corneal epithelial defects.

Methods:: Six patients presenting with persistent corneal epithelial defects were included in the study. The etiologies of the ulcers were: neurotrophic (N=3), post-herpetic (N=2) and traumatic (N=1). PRGF treatment requires that platelet and plasma protein extracts be obtained from the patient. Thus, blood was collected in 3.8% (wt/vol) sodium citrate as anticoagulant. Plasma was separated into two fractions, each with a distinct concentration of platelets and growth factors. PRGF was activated by adding calcium chloride (50 ml) to fraction 2 followed by incubation at 37ºC. Calcium acts as a necessary cofactor for platelet aggregation. One drop of undiluted PRGF was applied every two hours until epithelial closure.

Results:: PRGF promoted the complete repair of persistent corneal epithelial defects which were poorly or non-responsive to conventional therapy. No side effects were observed and a follow up after 3 months showed no signs of relapse.

Conclusions:: These preliminary findings indicate that persistent corneal epithelial defects respond to topical application of PRGF, probably due to its high concentration of growth factors. This treatment is currently being subjected to further evaluation.

Keywords: cornea: clinical science • wound healing • growth factors/growth factor receptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.